Clinical Trials · NCT05236517
A Research Study Looking at How 50 mg Semaglutide Daily Affects Food Intake and Emptying of the Stomach in People With Obesity
- Phase
- Phase 1
- Recruitment status
- Completed
- Sponsor
- Novo Nordisk A/S
- Enrollment
- 60
- Start date
- Feb 2022
- Locations
- 1 site, Germany
- Primary endpoint
- Relative change in energy intake during ad libitum lunch